Mike Crapo Stock Trades

Mike Crapo Trading Disclosure Profile | Quantellect Mike Crapo Trading Disclosure Profile | Quantellect

Mike Crapo's public disclosure record shows a single transaction: a joint purchase filed nearly nine years ago. For Idaho's Republican senator, that is a remarkably thin trading footprint, and it tells investors more about disclosure mechanics than about an active trading strategy.

The lone entry dates to November 27, 2017, when a joint purchase valued between $50,001 and $100,000 was made in Pharma Partners, LLC, an entity listed in Englewood, Colorado. The filing describes the firm as funding research and clinical trials on a class of drugs called metalloporphyrins, with lead candidates identified as BMX-010 and BMX-001. The transaction was reported under the "Joint" attribution code, meaning it was attributed jointly rather than solely to the senator. The purchase was disclosed on December 6, 2017, nine days after the transaction date and within the reporting window established by the Stop Trading on Congressional Knowledge Act of 2012.

A Single Filing, Not a Trading Pattern

One transaction does not establish a pattern, a sector preference, or a change in behavior over time. The data contains one transaction in calendar year 2017: one purchase and no sales. There is no second period to compare it against, so no claim about frequency increasing, decreasing, or shifting can be supported. What can be said is narrower: this is the only disclosed trade on record for Crapo, and no ticker is recorded for the security. As a result, there is no ticker-specific trading activity to summarize.

Because the disclosure concerns an LLC described as funding drug research and clinical trials, the filing does not map to a supplied sector classification. The sector field for this transaction is recorded as unknown. Readers should not infer anything beyond that missing classification. The transaction description identifies metalloporphyrins and the BMX-010 and BMX-001 drug candidates, but the data supplies neither a sector nor an industry label for the transaction.

Crapo's disclosure record can be placed alongside the broader congressional population counts. Among the 100 sitting senators measured on August 22, 2026, 39 have no disclosed trades, while the broader pool of 537 sitting members of Congress includes 276 with zero disclosed trades. Crapo is not in that zero-trade group: his record contains one joint purchase dated November 27, 2017, with no additional transactions listed.

No Quantellect Score is currently available for Crapo. As of the latest published score date, August 21, 2026, 76 members had a published score, including 73 sitting members. The available data states that no score row exists for Crapo at that latest published score date.

For investors researching Crapo's financial disclosures, the practical takeaway is straightforward: the public record offers one data point, a joint purchase in an LLC described as funding pharmaceutical research and clinical trials. The transaction was reported in the $50,001-to-$100,000 disclosure range, carries no ticker or supplied sector classification, and was disclosed nine days after its November 27, 2017 transaction date. There is no repeated activity across years or securities in this record from which to establish a broader trading pattern.

Disclosure and Methodology Note

This profile is based solely on data drawn from official congressional financial disclosure filings and Quantellect's transaction database. Transactions filed under a "Joint" attribution are reported jointly and should not be read as reflecting the senator's individual investment decision alone. Prompt transaction-reporting requirements for members of Congress are set out in the Stop Trading on Congressional Knowledge Act of 2012, and further guidance is available from the Senate Select Committee on Ethics. The source filing referenced in this profile can be viewed through the Senate Electronic Financial Disclosure system. This content is for informational purposes only and does not constitute investment advice.